Longitudinal Sensitivity of Alzheimer's Disease Severity Staging.

Am J Alzheimers Dis Other Demen

PD Neuroscience, Roche Pharma, Basel, Switzerland.

Published: February 2021

Understanding Alzheimer's disease (AD) dynamics is essential in diagnosis and measuring progression for clinical decision-making; however, clinical instruments are imperfect at classifying true disease stages. This research evaluates sensitivity and determinants of AD stage changes longitudinally using current classifications of "mild," "moderate," and "severe" AD, using Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), and the Clinical Dementia Rating-Sum of Boxes (CDR-SB) thresholds. Age and pre-progression rate were significant determinants of AD progression using MMSE alone to stage AD, and pre-progression was found to impact disease progression with CDR-SB. Sensitivity of these instruments for identifying clinical stages of AD to correctly staging a "moderate" level of disease severity for outcomes MMSE, CDR-SB, and ADAS-Cog was 92%, 78%, and 92%, respectively. This research derives longitudinal sensitivity of clinical instruments used to stage AD useful for clinical decision-making. The MMSE and ADAS-Cog provided adequate sensitivity to classify AD stages.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624049PMC
http://dx.doi.org/10.1177/1533317520918719DOI Listing

Publication Analysis

Top Keywords

alzheimer's disease
12
longitudinal sensitivity
8
disease severity
8
clinical decision-making
8
clinical instruments
8
disease
6
clinical
6
sensitivity alzheimer's
4
severity staging
4
staging understanding
4

Similar Publications

Alzheimer's disease (AD) is the most frequent cause of dementia. Since there are complex pathophysiological mechanisms behind AD, and there is no effective treatment strategy, it is necessary to introduce novel multi-targeting agents with fewer side effects and higher efficacy. Polydatin (PD) is a naturally occurring resveratrol glucoside employing multiple mechanisms toward neuroprotection.

View Article and Find Full Text PDF

Background: ApoE polymorphism especially APOE ε4 play a central role in AD pathophysiology through Aβ-dependent and Aβ-independent neuropathogenic pathway in the Alzheimer's disease.

Method: A cross-sectional study was performed on non diseased and diseased subjects with stroke from outpatient services of Neurology department of Institute of Human Behavior & Allied Sciences (IHBAS), New Delhi (India). Subjects diagnosed with various dementias including Alzheimer's disease, non AD dementias and dementia with Behavior & Psychological symptoms were taken.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

Background: Drugs targeting Alzheimer's disease (AD) pathology are likely to be most effective in the presymptomatic stage, where individuals harbor AD pathology but have not manifested symptoms. Neuroimaging approaches can help to identify such individuals, but are costly for population-wide screening. Cost-effective screening is needed to identify those who may benefit from neuroimaging, such as those at risk of developing clinical disease.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Laboratory of Clinical Investigation, National Institute on Aging, Intramural Research Program, Baltimore, MD, USA.

Background: Neurite degeneration is increasingly suspected to represent a causal feature of mild cognitive impairment (MCI) and Alzheimer's disease (AD). Therefore, sensitive and specific imaging biomarkers of neuronal degeneration are needed to elucidate the mechanisms underlying cognitive impairment in MCI and AD. However, the recently developed Neurite Orientation Dispersion and Density Imaging (NODDI) MRI technique, used to measure the neurite density index (NDI), has some limitations.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

The Fourth People's Hospital of Chengdu, Chengdu, Sichuan, China.

Background: Apolipoproteins and cortical morphology are closely associated with memory complaints, and both may contribute to the development of Alzheimer's disease.

Method: A total of 97 patients from the University of Electronic Science and Technology (UESTC) (n=42) and the Fourth People's Hospital of Chengdu (FPHC) (n=55) were grouped based on recruitment location, and underwent neuropsychological tests. ApoB, ApoA1, ApoB/ApoA1, plasma Alzheimer's biomarker, apolipoprotein E (ApoE) genotyping, 3T magnetic resonance imaging.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!